In May, the Government published a consultation on the draft UK air quality plan for tackling nitrogen dioxide. We are considering responses to the consultation and the final plan is due to be published by 31 July.<\/p>
<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4098", "label" : {"_value" : "Biography information for Dr Thérèse Coffey"} } , "answeringMemberConstituency" : {"_value" : "Suffolk Coastal"} , "answeringMemberPrinted" : {"_value" : "Dr Thérèse Coffey"} , "dateOfAnswer" : {"_value" : "2017-07-10", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2017-07-10T14:02:43.967Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "13"} , "answeringDeptShortName" : {"_value" : "Environment, Food and Rural Affairs"} , "answeringDeptSortName" : {"_value" : "Environment, Food and Rural Affairs"} , "date" : {"_value" : "2017-07-04", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Nitrogen Dioxide: Pollution Control"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Environment, Food and Rural Affairs, what steps he is taking to reduce the incidence of nitrogen dioxide levels exceeding the legal limit of 40 micrograms per cubic metre.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4573", "label" : {"_value" : "Biography information for Dr Rosena Allin-Khan"} } , "tablingMemberConstituency" : {"_value" : "Tooting"} , "tablingMemberPrinted" : [{"_value" : "Dr Rosena Allin-Khan"} ], "uin" : "2976"} , {"_about" : "http://data.parliament.uk/resources/748183", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/748183/answer", "answerText" : {"_value" : "
The costs of clinical negligence are rising due to a range of factors such as rising activity in the National Health Service, increasing life expectancy, costs of care and factors within the legal environment. We need to tackle this rising expenditure whilst ensuring that patients harmed by the NHS can access appropriate compensation and that the NHS is able to learn from mistakes and improve patient care.<\/p>
<\/p>
In February my Rt. hon. Friend the Secretary of State for Health met with the former Secretary of State for Justice (Elizabeth Truss) at which the Secretary of State for Health was informed that that there would be a change in the personal injury discount rate. This change will have a significant impact on the cost of clinical negligence and the effect on general practice indemnity costs is of particular concern. This is why alongside the announcement of a change to the rate the government announced that the Department will work closely with general practitioners (GPs) and Medical Defence Organisations to ensure that appropriate funding is available to meet additional costs to GPs, recognising the crucial role they play in the delivery of the NHS. Since that time the Ministry of Justice (MoJ) have consulted on proposals to change how the discount rate is set in future.<\/p>
The Department is working closely with MoJ on proposals to introduce fixed recoverable costs in clinical negligence cases which, if implemented, would reduce the disproportionality between damages and costs in lower value claims. The Department also recently completed a consultation on proposals to introduce a \u2018Rapid Resolution and Redress\u2019 scheme which, if implemented, would be an alternative compensation scheme for families who haveexperienced severe avoidable birth injury. This scheme is aimed at delivering a long-term reduction in these harmful events through investigation and learning and providing an improved experience for affected families. This would be a voluntary scheme which would not affect an individual's right to litigate.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1542", "label" : {"_value" : "Biography information for Philip Dunne"} } , "answeringMemberConstituency" : {"_value" : "Ludlow"} , "answeringMemberPrinted" : {"_value" : "Mr Philip Dunne"} , "dateOfAnswer" : {"_value" : "2017-07-12", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "2890"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2017-07-12T13:29:39.307Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2017-07-04", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "NHS: Negligence"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, what discussions he has had with the Secretary of State for Justice on preventing escalating clinical negligence costs in the NHS.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4573", "label" : {"_value" : "Biography information for Dr Rosena Allin-Khan"} } , "tablingMemberConstituency" : {"_value" : "Tooting"} , "tablingMemberPrinted" : [{"_value" : "Dr Rosena Allin-Khan"} ], "uin" : "2889"} , {"_about" : "http://data.parliament.uk/resources/748209", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/748209/answer", "answerText" : {"_value" : "
Ministers and Government officials have had a number of discussions with Vertex and NHS England in which the availability of Orkambi for the treatment of cystic fibrosis was raised.<\/p>
<\/p>
The National Institute for Health and Care Excellence (NICE) is the independent body that develops guidance for the National Health Service on whether new drugs and treatments represent a clinically and cost effective use of resources.<\/p>
<\/p>
NICE published final guidance on the use of Orkambi (lumacaftor-ivacaftor) for treating cystic fibrosis homozygous for the F508del mutation in July 2016 that does not recommend this treatment.<\/p>
<\/p>
Where NICE has not been able to recommend a treatment, funding decisions should be made by the relevant NHS commissioner, based on an assessment of the available evidence.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"} } , "answeringMemberConstituency" : {"_value" : "Winchester"} , "answeringMemberPrinted" : {"_value" : "Steve Brine"} , "dateOfAnswer" : {"_value" : "2017-07-12", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2017-07-12T09:12:44.797Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2017-07-04", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Lumacaftor/ivacaftor"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, what steps he is taking to secure an affordable price for Orkambi, to make it available to people with cystic fibrosis.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4573", "label" : {"_value" : "Biography information for Dr Rosena Allin-Khan"} } , "tablingMemberConstituency" : {"_value" : "Tooting"} , "tablingMemberPrinted" : [{"_value" : "Dr Rosena Allin-Khan"} ], "uin" : "2960"} , {"_about" : "http://data.parliament.uk/resources/748242", "AnsweringBody" : [{"_value" : "Home Office"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/748242/answer", "answerText" : {"_value" : "
The Home Office does not specifically collect data from police forces on acid attacks as part of its regular data collection. Acid attacks are included in published statistics within assaults with injury.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1561", "label" : {"_value" : "Biography information for Mr Nick Hurd"} } , "answeringMemberConstituency" : {"_value" : "Ruislip, Northwood and Pinner"} , "answeringMemberPrinted" : {"_value" : "Mr Nick Hurd"} , "dateOfAnswer" : {"_value" : "2017-07-11", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2017-07-11T12:41:39.357Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "1"} , "answeringDeptShortName" : {"_value" : "Home Office"} , "answeringDeptSortName" : {"_value" : "Home Office"} , "date" : {"_value" : "2017-07-04", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Crimes of Violence: Acids"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for the Home Department, whether there has been an increase in the number of acid attacks in 2017.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4573", "label" : {"_value" : "Biography information for Dr Rosena Allin-Khan"} } , "tablingMemberConstituency" : {"_value" : "Tooting"} , "tablingMemberPrinted" : [{"_value" : "Dr Rosena Allin-Khan"} ], "uin" : "2870"} , {"_about" : "http://data.parliament.uk/resources/748276", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/748276/answer", "answerText" : {"_value" : "
The costs of clinical negligence are rising due to a range of factors such as rising activity in the National Health Service, increasing life expectancy, costs of care and factors within the legal environment. We need to tackle this rising expenditure whilst ensuring that patients harmed by the NHS can access appropriate compensation and that the NHS is able to learn from mistakes and improve patient care.<\/p>
<\/p>
In February my Rt. hon. Friend the Secretary of State for Health met with the former Secretary of State for Justice (Elizabeth Truss) at which the Secretary of State for Health was informed that that there would be a change in the personal injury discount rate. This change will have a significant impact on the cost of clinical negligence and the effect on general practice indemnity costs is of particular concern. This is why alongside the announcement of a change to the rate the government announced that the Department will work closely with general practitioners (GPs) and Medical Defence Organisations to ensure that appropriate funding is available to meet additional costs to GPs, recognising the crucial role they play in the delivery of the NHS. Since that time the Ministry of Justice (MoJ) have consulted on proposals to change how the discount rate is set in future.<\/p>
The Department is working closely with MoJ on proposals to introduce fixed recoverable costs in clinical negligence cases which, if implemented, would reduce the disproportionality between damages and costs in lower value claims. The Department also recently completed a consultation on proposals to introduce a \u2018Rapid Resolution and Redress\u2019 scheme which, if implemented, would be an alternative compensation scheme for families who haveexperienced severe avoidable birth injury. This scheme is aimed at delivering a long-term reduction in these harmful events through investigation and learning and providing an improved experience for affected families. This would be a voluntary scheme which would not affect an individual's right to litigate.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1542", "label" : {"_value" : "Biography information for Philip Dunne"} } , "answeringMemberConstituency" : {"_value" : "Ludlow"} , "answeringMemberPrinted" : {"_value" : "Mr Philip Dunne"} , "dateOfAnswer" : {"_value" : "2017-07-12", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "2889"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2017-07-12T13:29:39.4Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2017-07-04", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "NHS: Negligence"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, what assessment he has made of the reasons for the increasing cost of clinical negligence cases.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4573", "label" : {"_value" : "Biography information for Dr Rosena Allin-Khan"} } , "tablingMemberConstituency" : {"_value" : "Tooting"} , "tablingMemberPrinted" : [{"_value" : "Dr Rosena Allin-Khan"} ], "uin" : "2890"} ], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 5, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]} }